---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-284579"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:39:51.106284+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics Q3 net loss narrows to $11.7M; secures $75M from GSK license and equity investment

## Summary
- Net loss $11.7M ($0.33/shr) vs $22.5M ($0.70/shr) in Q3 2021; revenue $2M down from $3.1M.
- Cash $50.4M at Sep 30; post-Q3 received $9M GSK equity, $66M upfront invoiced; runway extended beyond 2024.
- GSK license for tebipenem HBr closed; $66M upfront, $9M equity, up to $525M milestones plus tiered royalties.
- SPR720 Phase 2 trial initiated for NTM pulmonary disease; top line data expected 1H 2024.
- Kamal Hamed joined as CMO in Sep 2022; received inducement awards of 210k RSUs and 140k PSUs.

## SEC filing metadata
- accession: 0001193125-22-284579
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/0001193125-22-284579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/d189186d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-284579
- JSON: https://secwatch.observer/filing/0001193125-22-284579.json
- Plain text: https://secwatch.observer/filing/0001193125-22-284579.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/0001193125-22-284579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.